Coronary Artery Anomalies — Data and Dilemmas
In this episode of Pediatric & Congenital Heart Talks, Julie Brothers, MD, addresses risk stratification in coronary artery anomalies and poses an algorithm for treatment approaches.
Showing 1321 - 1330 of 1528 results
In this episode of Pediatric & Congenital Heart Talks, Julie Brothers, MD, addresses risk stratification in coronary artery anomalies and poses an algorithm for treatment approaches.
In this episode of Pediatric & Congenital Heart Talks, Matthew Jolley, MD, discusses how 3D imaging and computational modeling deepen the understanding of valve function.
In this episode of Pediatric & Congenital Heart Talks, Maryam Naim, MD, discusses identification, monitoring and reduction of neurological injury and physiological stressors.
In this episode of Pediatric & Congenital Heart Talks, Jonathan J. Rome, MD, reviews challenges of interventional therapies and introduces novel rerouting strategies.
In this episode of Pediatric & Congenital Heart Talks, Danielle Burstein, MD, reviews the pathophysiology of heart failure and effective strategies for cardiopulmonary rehab.
Dr. Paul Offit discusses the safety record of COVID-19 vaccines, including the magnitude of doses administered and the rare, but real, side effect called myocarditis. He also discusses the risk-to-benefit assessment of any medication and provides a historical context for why we would not expect new side effects caused by COVID-19 vaccines at this point.
Dr. Paul Offit explains how COVID-19 vaccines based on messenger RNA technology work.
Scientists at CHOP are pioneering gene therapy so people with these red blood cell disorders can go beyond just managing their chronic disease and live healthy lives.
Founded in 2002, the MPA comprises underrepresented in medicine (URiM) residents, fellows, and attending physicians who are committed to creating a diverse workforce that affords the best and most culturally competent care to the patients and families we treat.
Dr. Paul Offit discusses the possibility of reinfection with SARS-CoV-2, the potential consequences of such reinfections, and what our experience with reinfection means for COVID-19 vaccine development.